Clinical trial
Lapatinib in Treating Patients With Prostate Cancer That Did Not Respond to…
NCT00246753 · UNC Lineberger Comprehensive Cancer Center, Other · Completed
Key facts
| NCT number | NCT00246753 |
|---|---|
| Title | Lapatinib in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy |
| Official title | A Phase II Study of Oral Once Daily GW572016 (Lapatinib) In Patients With Hormone Refractory Prostate Cancer |
| Acronym | NRR |
| Lead sponsor | UNC Lineberger Comprehensive Cancer Center, Other |
| Collaborators | GlaxoSmithKline Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Prostate Cancer |
| Intervention type | Drug |
| Interventions | lapatinib ditosylate |
| Enrollment | 29 |
| Start date | Oct 1, 2005 |
| Primary completion | Jul 1, 2012 |
| Completion | May 1, 2013 |
| First posted | Oct 31, 2005 |
| Last update posted | Jun 28, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: